Icon Plc
Open
$116.19
Prev. Close
$116.11
High
$116.35
Low
$116.05
Market Snapshot
$9.03B
15.1
9.60
$8.28B
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 39,800 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
emptyResult
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 39,800 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Recently from Cashu
Icon Plc Receives Upgrade Amid Positive Outlook for Pharma Industry Growth
Icon Plc Poised for Growth Amid Positive Industry Shifts In recent developments, Wall Street analysts highlight a significant upgrade for Icon Plc (ICLR) from BMO, raising its rating to "outperform."…
Complex Analyst Ratings Highlight Divergent Views on Icon Plc's Market Position
Analysts’ Divergent Views Reflect Complex Landscape for Icon Plc In recent weeks, analysts offer a mixed bag of opinions on Icon Plc (NASDAQ: ICLR), a prominent player in the clinical research outsour…
Mixed Analyst Ratings Reveal Uncertainty Around Icon Plc's Future Performance
### Navigating the Diverging Analyst Ratings for Icon Plc In the past three months, five independent analysts evaluate Icon Plc's (NASDAQ: ICLR) performance, revealing a blend of optimistic and cautio…
Icon Plc Expands Services as CRO Demand Grows for FDA Breakthrough Pathways
CROs see rising demand as drugmakers chase expedited FDA pathways Clinical research organisations including Icon Plc are seeing increased demand as biopharma companies pursue expedited regulatory rout…